ATE301123T1 - 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten - Google Patents

2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten

Info

Publication number
ATE301123T1
ATE301123T1 AT02738404T AT02738404T ATE301123T1 AT E301123 T1 ATE301123 T1 AT E301123T1 AT 02738404 T AT02738404 T AT 02738404T AT 02738404 T AT02738404 T AT 02738404T AT E301123 T1 ATE301123 T1 AT E301123T1
Authority
AT
Austria
Prior art keywords
treatment
proliferative diseases
purine derivatives
substituted purine
pyrid
Prior art date
Application number
AT02738404T
Other languages
English (en)
Inventor
Peter M Fischer
Mike Jarman
Edward Mcdonald
Bernard Nutley
Florence Raynaud
Stuart Wilson
Paul Workman
Original Assignee
Cyclacel Ltd
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0115713A external-priority patent/GB0115713D0/en
Priority claimed from GB0120333A external-priority patent/GB0120333D0/en
Application filed by Cyclacel Ltd, Cancer Rec Tech Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE301123T1 publication Critical patent/ATE301123T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT02738404T 2001-06-27 2002-06-27 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten ATE301123T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0115713A GB0115713D0 (en) 2001-06-27 2001-06-27 New purine derivatives
GB0120333A GB0120333D0 (en) 2001-08-21 2001-08-21 New purine derivatives
PCT/GB2002/002962 WO2003002565A1 (en) 2001-06-27 2002-06-27 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
ATE301123T1 true ATE301123T1 (de) 2005-08-15

Family

ID=26246255

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738404T ATE301123T1 (de) 2001-06-27 2002-06-27 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten

Country Status (7)

Country Link
US (1) US7612079B2 (de)
EP (1) EP1399446B1 (de)
JP (1) JP4381804B2 (de)
AT (1) ATE301123T1 (de)
DE (1) DE60205376T2 (de)
GB (1) GB2378180B8 (de)
WO (1) WO2003002565A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
JP5006194B2 (ja) 2004-08-19 2012-08-22 ディーエスエム アイピー アセッツ ビー．ブイ． 高沸点の空気および／または温度感受性有用生成物の混合物の精留方法
CA2576159A1 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20100152210A1 (en) * 2007-03-28 2010-06-17 Neuro Search A/S/ Purinyl derivatives and their use as potassium channel modulators
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
FR2920776B1 (fr) * 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
US9408848B2 (en) 2008-08-15 2016-08-09 Georgetown University Fluorescent CDK inhibitors for treatment of cancer
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
AU2018213119B2 (en) 2017-01-26 2021-10-28 Cyclacel Limited Process for preparing purine derivatives
AU2020242304A1 (en) * 2019-03-20 2021-10-07 Aphp (Assistance Publique - Hôpitaux De Paris) Roscovitine analogues and use thereof for treating rare biliary diseases
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL277968A (de) * 1961-05-04
US3610721A (en) * 1969-10-29 1971-10-05 Du Pont Magnetic holograms
US3853676A (en) * 1970-07-30 1974-12-10 Du Pont Reference points on films containing curved configurations of magnetically oriented pigment
US3676273A (en) * 1970-07-30 1972-07-11 Du Pont Films containing superimposed curved configurations of magnetically orientated pigment
IT938725B (it) * 1970-11-07 1973-02-10 Magnetfab Bonn Gmbh Procedimento e dispositivo per otte nere disegni in strati superficiali per mezzo di campi magnetici
US3790407A (en) * 1970-12-28 1974-02-05 Ibm Recording media and method of making
US4011009A (en) * 1975-05-27 1977-03-08 Xerox Corporation Reflection diffraction grating having a controllable blaze angle
US4398798A (en) * 1980-12-18 1983-08-16 Sperry Corporation Image rotating diffraction grating
JPH0298811A (ja) * 1988-10-05 1990-04-11 Fuji Photo Film Co Ltd 磁気記録媒体
AU626983B2 (en) 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
US5192611A (en) * 1989-03-03 1993-03-09 Kansai Paint Co., Ltd. Patterned film forming laminated sheet
DE69218582T2 (de) * 1992-02-21 1997-07-10 Hashimoto Forming Kogyo Co Lackierung mit magnetisch hergestelltem Muster und lackiertes Produkt mit magnetisch hergestelltem Muster
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5672410A (en) * 1992-05-11 1997-09-30 Avery Dennison Corporation Embossed metallic leafing pigments
US5991078A (en) * 1992-08-19 1999-11-23 Dai Nippon Printing Co., Ltd. Display medium employing diffraction grating and method of producing diffraction grating assembly
JP2655551B2 (ja) * 1992-09-09 1997-09-24 工業技術院長 微細表面形状創成法
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
DE69431343T2 (de) * 1993-07-16 2003-07-31 Luckoff Display Corp Mit lichtbeugung arbeitende anzeigevorrichtung mit vollfarbfähigen einzelnen bildelementen unter verwendung refklektierten oder transmittierten lichtes
US6033782A (en) * 1993-08-13 2000-03-07 General Atomics Low volume lightweight magnetodielectric materials
DE69422246T2 (de) * 1993-08-31 2000-05-11 Control Module Inc Gesichertes optisches Identifikationsverfahren und die hierzu erforderlichen Mittel
JP3396924B2 (ja) 1993-09-07 2003-04-14 日本曹達株式会社 活性汚泥のバルキング防止剤
DE4335308C2 (de) * 1993-10-16 1995-12-14 Daimler Benz Ag Kennzeichnung von Fahrzeugen zur Erschwerung von Diebstahl und oder unbefugter Veräußerung
EP0665229B1 (de) 1994-02-01 1999-11-17 Ajinomoto Co., Inc. Verfahren zur Herstellung von Nukleinsäurebasenderivaten
US5424119A (en) * 1994-02-04 1995-06-13 Flex Products, Inc. Polymeric sheet having oriented multilayer interference thin film flakes therein, product using the same and method
US6110923A (en) 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
EP0874846B1 (de) * 1995-11-01 2003-04-02 Novartis AG Purinderivate und verfahren zu ihrer herstellung
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB9524862D0 (en) * 1995-12-06 1996-02-07 The Technology Partnership Plc Colour diffractive structure
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6103361A (en) * 1997-09-08 2000-08-15 E. I. Du Pont De Nemours And Company Patterned release finish
US6168100B1 (en) * 1997-10-23 2001-01-02 Toyota Jidosha Kabushiki Kaisha Method for producing embossed metallic flakelets
EP1042509A1 (de) * 1997-12-24 2000-10-11 The Regents of the University of California Verfahren durch gebrauch an oligonukleotidarrays zum suchen von neuen kinase-inhibitoren
TR200002482T2 (tr) * 1998-02-26 2002-10-21 Aventis Pharmaceuticals Inc. 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler
US6692031B2 (en) * 1998-12-31 2004-02-17 Mcgrew Stephen P. Quantum dot security device and method
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
TR200102714T2 (tr) * 1999-02-01 2002-01-21 Cv Therapeutics, Inc. Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6808806B2 (en) * 2001-05-07 2004-10-26 Flex Products, Inc. Methods for producing imaged coated articles by using magnetic pigments
US6749936B2 (en) * 2001-12-20 2004-06-15 Flex Products, Inc. Achromatic multilayer diffractive pigments and foils
US6841238B2 (en) * 2002-04-05 2005-01-11 Flex Products, Inc. Chromatic diffractive pigments and foils
US6692830B2 (en) * 2001-07-31 2004-02-17 Flex Products, Inc. Diffractive pigment flakes and compositions
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US6949644B2 (en) * 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives

Also Published As

Publication number Publication date
GB2378180A8 (en) 2009-10-21
GB2378180A (en) 2003-02-05
EP1399446A1 (de) 2004-03-24
DE60205376T2 (de) 2006-04-06
WO2003002565A1 (en) 2003-01-09
GB2378180B (en) 2004-01-28
DE60205376D1 (de) 2005-09-08
US20050009846A1 (en) 2005-01-13
JP2004521148A (ja) 2004-07-15
US7612079B2 (en) 2009-11-03
GB0214909D0 (en) 2002-08-07
GB2378180B8 (en) 2009-10-21
EP1399446B1 (de) 2005-08-03
JP4381804B2 (ja) 2009-12-09

Similar Documents

Publication Publication Date Title
ATE301123T1 (de) 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
MY135841A (en) Novel benzodioxoles
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
DE60318193D1 (en) Phenethanolaminderivate
TNSN04165A1 (en) Substituted hydroxyethylamines
NZ503407A (en) Anilide derivatives useful for treating inflammatory diseases
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
CA2401229A1 (en) Aryl fused azapolycyclic compounds
MY138352A (en) Benzothiazole derivatives
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
HK1074794A1 (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
PL396946A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
JO2321B1 (en) 4-phenyl-pyridine derivatives
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RS111204A (en) New compounds useful for the treatment of obesity,type ii diabetes and cns disorders
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
NO20020282D0 (no) Nytt difenylpiperidinderivat
DE50211929D1 (en) Pyrimidinderivate
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1399446

Country of ref document: EP